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Abstract 34 
DNA replication errors that persist as mismatch mutations make up the molecular fingerprint 35 
of mismatch repair (MMR)-deficient tumors and convey them with resistance to standard 36 
therapy. Using whole-genome and -exome sequencing, we here confirm an MMR-deficient 37 
mutation signature that is distinct from other tumor genomes, but surprisingly similar to germ-38 
line DNA, confirming that a substantial fraction of human genetic variation arises through 39 
mutations escaping MMR. Moreover, we identify a large set of recurrent indels that may 40 
serve to detect microsatellite instability (MSI). Indeed, using endometrial tumors with 41 
immunohistochemically-proven MMR deficiency, we optimize a novel marker set capable of 42 
detecting MSI and show it to have greater specificity and selectivity than standard MSI tests. 43 
Additionally, we show that recurrent indels are enriched for the 'DNA double-strand break 44 
repair by homologous recombination' pathway. Consequently, DSB repair is reduced in 45 
MMR-deficient tumors, triggering a dose-dependent sensitivity of MMR-deficient tumor 46 
cultures to DSB inducers. 47 
                48 
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Introduction 49 
MMR-deficiency represents a well-established cause of Lynch syndrome, which is an 50 
autosomal dominantly inherited disorder of cancer susceptibility triggered by loss-of-function 51 
mutations in MMR genes (MLH1, MSH2 or MSH6) 1. Lynch syndrome is responsible for 2-5% 52 
of endometrial (EM) or colorectal (CRC) tumors. Additionally, epigenetic silencing of MLH1 53 
contributes to another 15-28% of these tumors 2,3. Deficiency of the MMR machinery leads to 54 
DNA replication errors in the tumor tissue, but not the normal surrounding tissue. In 55 
particular, errors often accumulate as indel mutations in mono- and di-nucleotide repeats  a 56 
phenomenon referred to as microsatellite instability (MSI) 4. 57 
MMR-deficient tumors exhibit a different prognosis and therapeutic outcome after 58 
standard chemotherapy 5. Untreated CRC patients with MMR-deficient tumors have a 59 
modestly better prognosis, but do not seem to benefit from 5-fluorouracil-based adjuvant 60 
chemotherapy, which is the first-choice chemotherapy for CRC. In particular, in MMR-61 
deficient tumors mismatches induced by 5-fluorouracil are tolerated, leading to failure to 62 
induce cell death 6. MMR-deficient tumors are also resistant to cisplatin and carboplatin, 63 
which are frequently used chemotherapies in EM cancer 7. Furthermore, MMR-deficient 64 
tumors can be resistant to targeted therapies, because they acquire secondary mutations in 65 
genes that activate alternative or downstream signaling pathways (e.g., PIK3CA). Another 66 
possibility is that epigenetic silencing of MLH1 coincides with particular mutations, such as 67 
the BRAF V600E mutation 8, which represents an established negative predictor of response 68 
to targeted anti-EGFR therapies in advanced CRC 9. 69 
Efforts to individualize the treatment of MMR-deficient tumors have focused on 70 
identifying synthetic lethal interactions within the MMR pathway. In particular, increased 71 
oxidative damage (by methotrexate exposure or PINK1 silencing 10) and interference with the 72 
base excision repair (BER) pathway (by DNA polymerase  or  inhibition 11) can sensitize 73 
MMR-deficient tumors. Until now, these findings failed, however, to translate into clinically 74 
effective treatment options. Alternatively, as highlighted above, secondary mutations 75 
occurring because of MMR-deficiency may also critically determine therapeutic efficacy 12. 76 
These secondary mutation spectra have, however, poorly been characterized, mainly 77 
because studies often focused at one or a few reporter loci, or exclusively on mutations at 78 
known hotspot sequences. More recently, the first whole-exome sequencing of MMR-79 
deficient tumors was performed, highlighting the clearly distinct mutational landscape of 80 
these tumors 13 , whereas at the whole-genome level, Kim et al. revealed overrepresentation 81 
of MSI in euchromatic and intronic regions compared to heterochromatic and intergenic 82 
regions 14.  83 
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To generate a more comprehensive picture of the mutation spectra arising in MMR-84 
deficient tumors, and in particular, to interpret their clinical relevance with respect to 85 
diagnostically assessing MSI and therapeutically targeting MMR-deficient tumors, we here 86 
sequenced another comprehensive set of MMR-deficient tumors. In particular, whole-87 
genome and -exome sequencing was applied to 5 and 28 tumor-normal pairs, of which 88 
respectively 3 and 22 were MMR-deficient. 89 
90 
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Results 91 
Whole-genome sequencing of MMR-deficient tumors 92 
To select MMR-deficient tumors for whole-genome sequencing, standard diagnostic 93 
tests were used, including immunohistochemistry of MMR proteins (MLH1, MSH2 and 94 
MSH6), assessment of MSI using the extended Bethesda panel and methylation profiling of 95 
the MLH1 promoter. Three chemo-naïve EM tumors, either deficient for MLH1, MSH2 or 96 
MSH6 and thus covering the full spectrum of MMR-deficiency, as well as two MMR-proficient 97 
EM tumors were selected (Table 1). Different sequencing technologies were leveraged to 98 
avoid potential technology biases in assessing mutation patterns in MMR-deficient tumor 99 
genomes, i.e., Complete Genomics® (CG) and Illumina® short-read sequencing. We obtained 100 
high coverage sequencing data (30-120x) for tumor and matched normal samples (Table 1). 101 
Application of a standard annotation and filtering pipeline, as previously described15, revealed 102 
that each MMR-deficient tumor exhibited a clear hypermutator phenotype, containing on 103 
average 50 times more novel somatic mutations than MMR-proficient tumors (Figure 1a; 104 
Figure 1 – source data 1; Figure 1 – source data 2). Orthogonal technologies validated 98% 105 
of substitutions and 88% of indels in the 3 MMR-deficient tumors, while only 62% of 106 
substitutions and 11% of indels were validated in the 2 MMR-proficient tumors (Figure 1 – 107 
source data 3). This difference in validation rates between MMR-deficient and -proficient 108 
tumors is probably due to the fact that in normal genomes, as well as MMR-proficient tumor 109 
genomes, the number of true-positive indels is low in comparison to the number of false-110 
positive indels. However, in MMR-deficient tumors, due to their specific hypermutator 111 
phenotype, the number of true-positive indels is vastly increased, thereby rendering the false 112 
positive fraction proportionally much smaller. Notably, all tumors were negative for POLE 113 
mutations 16,17. 114 
Somatic mutation patterns in MMR-deficient hypermutators 115 
Studies in model organisms and cell lines have shown that somatic mutations arising 116 
due to MMR-deficiency mostly involve indels affecting microsatellite sequences (di- to hexa-117 
nucleotide repeats with a minimal length of 6 bases and at least two repeat units) and 118 
homopolymers (mononucleotide repeats with a minimal length of 6 bases) 18. We observed 119 
that indels were indeed more frequent than single basepair substitutions in all 3 MMR-120 
deficient tumors (Figure 1a). Indels predominantly affected homopolymers (40-fold 121 
enrichment over expected by chance) and to a lesser extent also microsatellites (2.3-fold 122 
enrichment; Figure. 1b; Figure 1 – figure supplement 1). Substitutions were only slightly 123 
enriched in homopolymers and microsatellites (3- and 1.5-fold enrichment, respectively; 124 
Figure 1b). Mutations occurred as frequent in introns as in the rest of the genome, but were 125 
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clearly less frequent in exons (excluding 5’ and 3’ untranslated regions (UTRs)). This 126 
decrease was caused by indels, which were 91% less frequent in exons (Figure 1c,d). 127 
Correction for the number of homopolymers, the length of homopolymers or their basepair 128 
composition in exons versus other regions weakened this effect, but failed to completely 129 
alleviate it (Figure 1e; Note S1; Figure 1 – figure supplement 2). Since 92% of exonic indels 130 
resulted in frameshift mutations, which have a greater functional impact than substitutions 19, 131 
this suggests that exonic indels are prone to negative clonal selection during tumorigenesis. 132 
Somatic substitutions in MMR-deficient hypermutators 133 
There is extraordinary variation in the frequency and spectrum of somatic mutations 134 
affecting different cancers, shedding light on the underlying mutational processes and 135 
disease etiology of these tumors 20. When assessing somatic substitutions in MMR-deficient 136 
tumors, we observed that 74% of all substitutions represent transitions (i.e., purine-to-purine 137 
or pyrimidine-to-pyrimidine substitutions), which is similar to the patterns observed in the 138 
matched germ-line of these tumors (Figure 2a). This is surprising, since tumor genomes 139 
generally display patterns distinct from those found in the germ-line. Indeed, when extending 140 
these analyses to other hypermutators, i.e., UV-light-induced melanoma 21, tobacco smoke-141 
induced small cell lung adenocarcinoma (SCLC) 22, as well as breast tumors deficient for 142 
BRCA1 23 or EM tumors proficient for MMR, patterns were clearly dissimilar from the 143 
matched germ-line (Figure 2a). On the other hand, de novo germ-line substitutions identified 144 
through whole-genome sequencing of parent-offspring trios 24,25, common genetic variation 145 
as catalogued by the 1000 Genomes Project (1KG) 26, and substitutions that occurred in the 146 
human lineage during the divergence of humans and chimpanzees correlated strongly to the 147 
MMR-deficient tumor genome (Figure 2a). Given these remarkable parallels, we 148 
hypothesized that MMR-deficient genomes hypermutate in a way that mirrors the processes 149 
driving genetic variation on a population level, albeit somatically and on a shorter time scale. 150 
To further assess the similarities between MMR-deficient mutation patterns and germ-151 
line genetic variability, we analyzed small-scale and large-scale context-dependent effects on 152 
substitution patterns. At the small-scale level, when assessing the effect of flanking 153 
nucleotides on substitution frequencies, the patterns of all 4 sets of germ-line genetic variants 154 
were highly correlated to MMR-deficient tumors (average R2=0.77), but less to the 4 other 155 
cancer genomes (average R2=0.45; Figure 2b,c), providing further support for our 156 
hypothesis. On a large-scale context, the number of intergenic substitutions per 1Mb in germ-157 
line genetic variability databases was similarly highly correlated to those in MMR-deficient 158 
genomes (average R2=0.67), but not to those in other cancer genomes (average R2=0.42; 159 
Figure 2d). This suggests that also on a large scale, substitutions are comparably distributed 160 
in MMR-deficient tumor genomes as in germ-line genomes. At the large-scale level, 9 161 
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genomic features are linked with genetic variability 27. Each of these features correlated 162 
significantly with substitution frequencies in MMR-deficient tumors and germ-line genomes. 163 
Linear modeling revealed that 6 of these independently correlated with substitution rates in 164 
MMR-deficient tumors as well as with germ-line substitutions (Figure 2e). Overall, the types 165 
as well as the narrow and broad context-dependencies of substitutions thus appear to be 166 
largely shared between germ-line and MMR-deficient genomes, suggesting that a 167 
considerable fraction of human genetic diversity arises through mismatches escaping MMR. 168 
 Since MMR-proficient tumors carried 50 times fewer substitutions and displayed 169 
more disparate substitution patterns than MMR-proficient tumors, the observed correlations 170 
can almost exclusively be attributed to the MMR-deficient phenotype of these tumors. As 171 
such, these correlations also provide novel insights into the functioning of the MMR system. 172 
First, replication timing correlated with transitions but not transversions in all 3 MMR-deficient 173 
tumors (Figure 2f). This contrasts with the increase in late S phase transversions observed in 174 
all other genomes studied here (Figure 2f), as well as in lymphoblastoid cell lines 28. The 175 
increase in MMR-proficient but not MMR-deficient cells suggests a reduced fidelity of DNA 176 
repair in late S phase, leading to an increase in transversions. Potential causes include a 177 
decreased MMR-activity in late S phase, or a longer window of time available for the repair of 178 
early versus late transversions in MMR-proficient cells29. In contrast, DNA repair fidelity in 179 
MMR-deficient cells is invariably low and therefore not affected by replication time. Secondly, 180 
a positive association with simple repeat content was noted. Indeed, a 1.6-fold increase in 181 
substitutions at bases immediately flanking simple repeats was noted, with a 3-fold increase 182 
next to homopolymers and a 1.3-fold increase next to microsatellites (Figure 2g). These 183 
substitutions for the vast majority converted the base flanking the repeat, to the base 184 
constituting the repeat (Figure 2g). They are thus probably the result of polymerase slippage 185 
events, following a mechanism akin to the previously described bacterial dislocation 186 
mutagenesis 30. Thirdly, G:C>A:T transitions in CpG sites strongly depend on CpG content, 187 
but are inversely correlated with the fraction of CpG islands (Figure 2e). Spontaneous, 188 
replication-independent deaminations of methyl-C to T underlie such transitions. Here, the 189 
much larger increase in CG>TG transitions observed in MMR-deficient compared to MMR-190 
proficient tumors (3,449 versus 145) demonstrates that replication-independent MMR, 191 
recently described at the molecular level 31,32, is also involved in deamination repair in vivo 33. 192 
Finally, overall substitution frequencies correlated inversely with CpG islands. Indeed, 193 
irrespective of dinucleotide context, bases outside CpG islands were nearly two times more 194 
likely to undergo mutation than those inside CpG islands (Figure 2h). As CpG islands are 195 
generally unmethylated, DNA methylation thus appears to contribute to the mutagenic 196 
process. Explanations for this observation include the polymerase stalling that DNA 197 
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methylation may induce 34, and the repair of spontaneously deaminated methyl-Cs, which is 198 
error-prone and thus mutagenic on its own 33. 199 
Somatic indels in MMR-deficient hypermutators 200 
We also evaluated somatic indel patterns in MMR-deficient tumors. As expected, 201 
since the majority of indels was located in homopolymers, a strong correlation between 202 
simple repeats and indel frequency was observed (Figure 3a). Indels were also 203 
predominantly 1 or 2 bps in length (Figure 3b). Although the minority of homopolymers 204 
consists of C or G bases (7%), an even smaller fraction of indels affected C:G homopolymers 205 
(1.9%; Figure 3c), suggesting that C:G homopolymers are less likely to accumulate indels. 206 
As observed in other MMR-deficient tumors tumors and also in MMR-deficient C. elegans 207 
14,35, deletions were remarkably more frequent than insertions (81% versus 19%), confirming 208 
that DNA polymerases are more prone to remove than to add a base during DNA synthesis.  209 
Exome-sequencing of additional MMR-deficient tumors 210 
Next, we selected 13 additional MMR-deficient tumors, as well as 4 MMR-proficient 211 
tumors, collected from different tissues (i.e., endometrium, colon and ovarium). Of these, 6 212 
represented primary tumor cultures of low passage, which we preferred over cell lines, 213 
because the latter due to their hypermutator phenotype are no longer representative of the 214 
original tumor (Figure 4 – source data 2). Exome-sequencing of tumor and matched germ-215 
line DNA at an average coverage of 44x revealed that each MMR-deficient tumor contained 216 
~2,015 somatic events versus 39 for MMR-proficient tumors (52-fold increase; Figure 4a; 217 
Figure 4 – source data 1; Figure 4 – source data 2). Validation rates for substitutions and 218 
indels were respectively 87% and 86%. Clustering analysis of all 13 MMR-deficient tumors 219 
for the genes affected by either a somatic substitution or indel in the coding regions revealed 220 
no obvious subgroups in terms of cancer of origin or between primary tumors and cell 221 
cultures (Figure 4 – figure supplement 1). Presumably because of negative clonal selection 222 
and differences in homopolymer content in exons versus other genomic regions, exonic 223 
substitutions outnumbered indels (Figure 4a; Figure 4 – figure supplement 2), similar to what 224 
we observed in the MMR-deficient whole-genomes (Figure 1c,d). Only a minority of these 225 
indels affected microsatellites, confirming that homopolymers were most frequently affected 226 
by indels.  227 
Remarkably, 1.6% of homopolymers was recurrently affected by an indel in the 16 228 
MMR-deficient tumors that underwent whole-genome or exome sequencing (i.e., 2,244 out of 229 
29,663 homopolymers were affected at least once, whereas 477 were affected at least twice; 230 
Figure 4 – figure supplement 3). Furthermore, 34 and 10 homopolymers were affected in ≥6 231 
or ≥8 tumors (Figure 4 – source data S3). In contrast, only 55 substitutions were recurrent, 3 232 
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of which were found in ≥2 tumors (i.e., two substitutions affecting KRAS codon 12 and 13 233 
were found in 3 and 4 tumors 36, whereas a substitution in ZNF648 affected 3 tumors). When 234 
comparing homopolymer content of coding regions versus UTRs, long homopolymers (>10 235 
bps) were more frequent in UTRs than in coding regions (Figure 4b). Because these long 236 
homopolymers were also more frequently affected (Figure 4c), the overall indel rate in coding 237 
regions was lower than in UTRs (Figure 4d). As a consequence of this difference, recurrent 238 
indels also occurred more frequently in UTRs than coding regions (31,438 versus 1,337; 239 
Figure 4 – source data 3). Remarkably, however, recurrent indels were more frequently 240 
observed than expected based on indel frequency in short, but not in long homopolymers 241 
(Figure 4e; Figure 4 – figure supplement 4). This suggests that features other than 242 
homopolymer length underlie indel recurrence rates. Positive clonal selection of indels 243 
affecting short homopolymers, which are predominant in coding regions, represents a 244 
possible explanation. Very similar results were obtained when the analysis was repeated only 245 
on the 13 whole-exomes, indicating that exonic mutations identified from whole-genome 246 
sequences did not introduce any bias.  247 
Recurrent indels reliably detect MSI in various cancer types 248 
The extended Bethesda panel, which consists of 8 microsatellite and 2 homopolymer 249 
markers, is currently used to diagnostically assess MSI 4. This panel was historically 250 
compiled from a limited set of markers known to be variable. Due to their length and 251 
variability, these markers are notoriously difficult to analyze and interpret. As a consequence, 252 
the Bethesda panel has reduced sensitivity to detect MSI. In an effort to improve MSI testing, 253 
we randomly selected 59 recurrent indels affecting ≥6 out of 16 tumors; 50 markers were in 254 
5’ or 3’UTRs and 9 were in coding regions (Figure 5 – source data 1). Furthermore, each of 255 
the markers was detected in both MMR-deficient EM and CRC. To facilitate high-throughput 256 
genotyping, the maximal length of affected homopolymers was restricted to 12 bps. First, we 257 
applied these 59 markers to a discovery set of 236 EM tumors for which MMR 258 
immunohistochemistry (IHC) data were available. This allowed us to determine 3 positive 259 
markers as the threshold with the best Matthew correlation coefficient to detect MMR-260 
deficiency based on IHC and thus to define MSI (Figure 5a,b). At this threshold, our markers 261 
detected 40 out of 41 tumors MMR-deficient on IHC (sensitivity98%), while only 1 out of 184 262 
MMR-normal tumors on IHC were identified as MSI (specificity>99%). Notably, the latter 263 
patient had a familial history of cancer within the Lynch spectrum, suggesting that the tumor 264 
indeed exhibited MSI. Secondly, after having optimized the marker threshold, a head-to-head 265 
comparison against Bethesda panel was performed in 114 independent EM tumors as a 266 
validation. When observing discordances, we assessed MMR-deficiency using IHC to 267 
address which of both MSI panels was correct. Briefly, each MSI tumor on Bethesda (>2 268 
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markers positive) was also MSI with the 59-marker panel (Figure 5c). However, 12 tumors 269 
were positive in the 59-marker panel, but negative in Bethesda. IHC on the 9 discordant 270 
tumors for which a paraffin block was available confirmed that each of them was MMR-271 
deficient either for MLH1 or MSH2, indicating that the 59-marker panel has a higher 272 
sensitivity compared to Bethesda.  273 
Likewise, we assessed MSI in 126 stage II or III CRC tumors. Each of the 28 MSI 274 
tumors on Bethesda was also positive with our 59-marker panel. In contrast, one tumor was 275 
MSI-positive in the 59-marker panel but not in the Bethesda panel (Figure 5d). This tumor 276 
contained a V600E BRAF mutation and was MLH1 hypermethylated, indicating that it was 277 
MMR-deficient and that our panel was also more sensitive for CRC 37. Finally, we also 278 
assessed whether our 59-marker panel can detect MSI in other cancer types. In a limited set 279 
of ovarian tumors and leukemias, we indeed correctly identified MSI in each of the samples 280 
tested (Figure 5 – source data 2).  281 
MMR-deficient tumors are enriched in indels affecting DSB repair  282 
Since we observed clear signs of clonal indel selection in MMR-deficient tumors, we 283 
assessed whether specific pathways were enriched for indels. We focused on frameshift 284 
indels in exons and exon/intron boundaries as they represent loss-of-function mutations 38 285 
and thus have a less ambiguous functional impact than indels in UTRs. On average, each 286 
MMR-deficient tumor contained 472 such indels, 59 of which were recurrent indels. Pathway 287 
analyses using IPA® of all genes affected by a somatic indel, excluding the core MMR genes, 288 
ranked the “Role of BRCA1 in DNA damage response” as the top enriched pathway. IPA® 289 
analysis of genes affected by recurrent indels moreover revealed that the “Double-strand 290 
break repair by homologous recombination” pathway (DSBR by HR) ranked top (Table 2). 291 
We also performed pathway analyses using the more advanced GenomeMuSiC, which takes 292 
background mutation rates into account and assigns weights depending on the number of 293 
tumors and genes affected in a given pathway. GenomeMuSiC analyses based on either the 294 
independently assembled Reactome or BioCarta pathway databases, ranked respectively the 295 
“ATR/BRCA pathway and the DNA repair” pathway first, with the more specific “Homologous 296 
recombination repair” pathway ranking third in the latter (Table 2). Based on an expert 297 
curated DNA repair database (DNARepairDB), “Homologous recombination” represented the 298 
only DNA repair pathway that was significantly enriched in indels. Since each pathway 299 
database differed with respect to the genes included, we finally compiled a literature-based 300 
set of genes with proven involvement in DSBR by HR, allowing us to more accurately 301 
estimate that each MMR-deficient tumor on average contained 3.3±0.4 indels in the “DSBR 302 
by HR” pathway (Table 2; Table 2 – figure supplement 1; Table 2 – source data 1). Notably, 303 
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none of the top-ranking pathways for any of the databases contained significantly more 304 
homopolymers in their genes than expected. 305 
In an effort to replicate these findings, we analyzed mutation data of 27 CRC and 65 306 
EM tumors with MSI sequenced by The Cancer Genome Atlas 13,16. Although most of these 307 
tumors were sequenced at low coverage depth, we identified 2,183 and 3,138 mutated genes 308 
from respectively the CRC and EM tumor datasets. IPA analysis confirmed that the Role 309 
of BRCA1 in DNA damage response was again amongst the top enriched pathways for each 310 
of the datasets. The corresponding P-values were 9.06E-3 and 2.97E-4, although only the 311 
latter survived multiple testing correction (P=0.022; Table 2 – source data 1). As raw 312 
datasets were not accessible, the more sensitive GenomeMuSiC could not be used. 313 
Reduced DSBR by HR activity in primary MMR-deficient cells 314 
Homozygous mutations affecting genes in the DSBR by HR pathway cause DSB 315 
repair defects reminiscent of BRCA1 or -2 loss, a phenotypic feature dubbed BRCAness 39. 316 
Having established that MMR-deficient tumors are enriched in heterozygous frameshift 317 
mutations in the DSBR by HR pathway, we investigated the functional impact of these 318 
events. First, we confirmed that indels affecting the DSBR by HR pathway were located in 319 
the major tumor subclone. Then, we analyzed HR in 7 MMR-deficient and 4 MMR-proficient 320 
patient-derived primary tumor cultures. We exposed these cultures to the PARP inhibitor 321 
olaparib, which induces DSBs upon DNA replication through single-strand break repair 322 
inhibition, and to mitomycin C, which induces DSBs through DNA cross-links and replication 323 
fork collapse 40. We then quantified the relative number of cells with γH2AX- and RAD51-324 
positive foci, respectively, as a measure of induced DSBs and ongoing HR. Exposure to 325 
olaparib or mitomycin C triggered an increase in γH2AX-foci in all tumor cultures, regardless 326 
of MMR status. In contrast, although RAD51 foci formation was evident in MMR-deficient and 327 
MMR-proficient cultures, the increase was far less pronounced in MMR-deficient cultures 328 
(Figure 6a,b), and this for both olaparib (P=0.021) and mitomycin C (P=0.006) exposure. The 329 
reduction in RAD51 foci could not be ascribed to differences in RAD51 protein expression or 330 
differences in cell cycle between MMR-deficient and -proficient cells, as these were similar 331 
between both sets of cultures, under both treated and untreated conditions (Figure 6 – figure 332 
supplement 1-3). Since RAD51 foci are completely absent upon PARP inhibition in cells with 333 
homozygous loss of BRCA1, but not affected in heterozygous mutation carriers 41, these ex 334 
vivo data suggest that the accumulation of indels in MMR-deficient tumors gradually impairs 335 
the DSBR by HR pathway to a level that is intermediate to that of cells heterozygous and 336 
homozygous-deficient for BRCA1. 337 
 338 
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DSB inducers sensitize MMR-deficient tumors 339 
As MMR-deficient tumors are compromised in their DSBR by HR activity, we 340 
wondered whether these tumors, similar to BRCA1-deficient tumors 41, are more sensitive to 341 
agents that induce DSBs. First, since PARP inhibitors are already used in clinical practice, all 342 
7 MMR-deficient and 4 MMR-proficient cultures were dose-dependently exposed to olaparib. 343 
This revealed that MMR-deficient cultures exhibited a dose-dependent decrease in 344 
proliferation upon exposure to olaparib, whereas MMR-proficient cultures were only affected 345 
at higher concentrations. Likewise, cell cytotoxicity assays revealed a dose-dependent 346 
sensitivity of MMR-deficient cells to olaparib that was more pronounced than in MMR-347 
proficient cells (50% growth inhibition (GI50) was reached at 26µM versus 129µM, 348 
respectively, P=0.0064 (Figure 7a,b; Figure 7 – figure supplement 1). Other DSB-inducing 349 
compounds such as mitomycin C or ionizing radiation similarly proved more detrimental for 350 
MMR-deficient than MMR-proficient cells (Figure 7b). In contrast, cytotoxicities of other 351 
chemotherapeutic compounds such as paclitaxel were comparable between both groups.  352 
Finally, in order to more accurately measure the level of HR-deficiency in MMR-353 
deficient tumors, we assessed the level of knock-down of BRCA1, BRCA2 and ATR needed 354 
to achieve an olaparib sensitivity similar to that observed in MMR-deficient cells, i.e. a GI50 355 
of 26µM. BRCA1, BRCA2 or ATR expression was dose-dependently reduced using siRNAs 356 
in the MMR- and HR-proficient cell line, MCF7. A growth inhibition of 50% was reached in 357 
MCF7 cells when applying 5.9nM ATR, 0.88nM BRCA1 or 0.41nM BRCA2 siRNA, 358 
corresponding respectively to a reduction in expression of 69.5±1.1%, 76.1±4.4% and 359 
80.0±2.4% (Figure 7c). These data thus suggest that the loss of DSBR by HR activity in 360 
MMR-deficient tumors corresponds to a loss of about 75-80% BRCA1 or -2 expression. 361 
362 
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Discussion 363 
Here, we surveyed whole-genomes of MMR-deficient tumors to provide a 364 
comprehensive picture of the mutations associated with human MMR-deficiency. With 365 
respect to somatic substitutions, we observed that the majority represented transitions and 366 
not transversions, and that adjacent nucleotides and various genomic features had an 367 
important context-dependent effect on determining which nucleotides were affected. 368 
Remarkably, the observed substitution pattern, in particular how it was impacted by small 369 
and large-scale contexts, was very similar to that in the germ-line at different time scales: for 370 
germ-line substitutions as they currently arise (de novo), as they have accumulated in the 371 
human population or as they served as a substrate for human-chimpanzee divergence 27. 372 
Our observations thus suggest that, similar to bacterial populations and other lower 373 
organisms 42, incomplete mismatch repair in humans contributes significantly to genetic 374 
variability and probably also to natural selection through genetic adaptation. Additionally, our 375 
data provide fundamental insights into the function of the MMR machinery. We observed, for 376 
instance, a higher number of substitutions in methylated CpG sequences, implicating MMR in 377 
the repair of methylated cytosine deamination and demonstrating that MMR disconnected 378 
from the replication fork is also critical to maintain genomic integrity. 379 
At the whole-genome level, 80% of somatic mutations represented indels. Although 380 
indel detection using high-throughput sequencing is burdened with high false-positive rates, 381 
88.0% of the indels identified here validated favorably using orthogonal technologies. When 382 
focusing on the clinical relevance of indel mutation patterns to diagnose MSI, we observed 383 
that indels specifically affected homopolymer stretches, which is relevant as the extended 384 
Bethesda panel consists of 8 microsatellite and only 2 homopolymer markers and possibly 385 
therefore has only limited sensitivity relative to IHC (~75% for both EM and CRC tumors 43-386 
45). Our 59-marker panel consisting only of markers in homopolymers was clearly more 387 
sensitive than Bethesda, yielding sensitivity rates of 87% relative to IHC. This was not due to 388 
the fact that we genotyped more markers than Bethesda, as restricting our panel to 10 389 
markers still resulted in a sensitivity rate of 85% (data not shown). Furthermore, since our 390 
panel was based on recurrent mutations present in both CRC and EM, and since 50 out of 59 391 
markers were located in UTRs, which are less likely to drive clonal selection and thus to 392 
represent tissue-specific events, it could be used to detect MSI in cancers affecting various 393 
tissues. Finally, since all markers were located in homopolymers ≤12 bps in length, they are, 394 
in contrast to the 25 or 26 bps markers from Bethesda, compatible with various low- to high-395 
throughput genotyping technologies, thereby greatly facilitating their clinical adoption. For 396 
instance, we were able to multiplex all 59 markers in just 5 PCR amplification reactions 397 
compatible with Sequenom MassArray genotyping. 398 
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Pathway analyses on all genes affected by exonic indels further revealed that the 399 
DSBR by HR pathway was enriched for somatic indels. Although mutations in genes involved 400 
in this pathway, such as MRE11A or RAD50, have previously been reported in MMR-401 
deficient tumors, these studies focused on specific mutations in individual genes rather than 402 
on pathways, and for this reason could establish that only a fraction of MMR-deficient tumors 403 
was affected by mutations in these genes 46. In contrast, our study identified that every MMR-404 
deficient tumors was affected by on average 3.3 somatic indels in the DSBR by HR pathway. 405 
Furthermore, although it is well established that cells deficient in BRCA1, BRCA2, Fanconi 406 
anemia or other HR-related genes, are hypersensitive to DSB inducers 47, as for instance, 407 
synthetic lethality in BRCA1 or BRCA2-deficient tumors through PARP inhibition is already 408 
approved as therapy in breast and ovarian cancer 48, data demonstrating sensitivity of MMR-409 
deficient cells to DSB inducers have not been conclusive 49-51. For instance, although there 410 
are some reports highlighting the sensitivity of MSH3-deficient cell lines to DSB inducers, this 411 
appeared to occur through a non-canonical MMR pathway, as MLH1 was not involved in this 412 
process 49,50. Furthermore, the only clinical study set-up so far to explore efficacy of PARP 413 
inhibitors as a single-agent therapy in previously treated patients with metastatic CRC 414 
stratified by MSI status, was unfortunately delayed due to patient accrual issues. 415 
Our hypothesis-free discovery that DSBR by HR is the top pathway affected by 416 
heterozygous loss-of-function mutations in MMR-deficient tumors, both in our own dataset 417 
and TCGA, also suggests that mutations in DSBR by HR genes converge in an oligogenic 418 
model, wherein the number of indels dose-dependently decrease DSBR by HR activity, 419 
thereby rendering them gradually more sensitive to DSB inducers. As a result of this double-420 
hit, our ex vivo culture experiments are, however, difficult to compare to experiments relying 421 
on genotype-matched cells that have a single hit in the MMR or HR pathway. In addition, 422 
since MMR and DSB by HR pathway activities are not characterized in a clinical setting, it is 423 
difficult to relate our data to clinical studies assessing the outcome of therapeutics such as 424 
cisplatin or 5-fluorouracil, which have potential opposing activities on MMR- and HR-deficient 425 
tumors. 426 
Clinical studies are therefore needed to assess whether DSB inducers, such as 427 
PARP inhibitors, are indeed also effective in MSI tumors. In particular, since on average 3.3 428 
heterozygous loss-of-function mutations only partially inactivate the DSB repair by HR 429 
pathway (80% inactivation), it remains to be seen whether, compared to BRCA1 or BRCA2-430 
deficient tumors, in which the HR pathway is completely inactivated, clinically relevant 431 
benefits are also achievable in MSI tumors. Possibly, only those MMR-deficient tumors 432 
containing large numbers of indels (5) in the DSBR by HR pathway will show a significant 433 
response. Nevertheless, there is great clinical need for novel treatment options in MSI 434 
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tumors. Indeed, although stage II or III CRC tumors with MSI are characterized by a modestly 435 
improved prognosis, MSI tumors in the advanced setting are generally associated with more 436 
peritoneal metastasis and a worse overall survival independent of the chemotherapy regimen 437 
52,53. Our observations thus clearly warrant novel clinical studies assessing the therapeutic 438 
efficacy of DSB inducers in MMR-deficient tumors. 439 
  440 
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Materials and methods 441 
 442 
Standard diagnostic tests for MMR-deficiency: To assess MLH1-, MSH2- and MSH6- 443 
deficiency immunohistochemistry using monoclonal antibodies against MLH1 (DAKO, clone 444 
ES05), MSH2 (BD Pharmagen, clone G219-1129) and MSH6 (Epitomics, clone EP49) were 445 
applied. Absence of nuclear staining in tumor cells and normal staining in the surrounding 446 
normal tissue were considered as MMR-deficient. Methylation of the MLH1 promoter was 447 
determined using the SALSA MS-MLPA KIT (MRC-Holland). PCR reaction fragments 448 
covering the Deng C and Deng D regions were separated by capillary gel electrophoresis 449 
(ABI 3130, Applied Biosystems) and quantified using the Genemarker (v1.91) software 450 
(Softgenetics). MSI status was detected by the extended Bethesda panel using capillary gel 451 
electrophoresis, as described previously 54,55. 452 
Sample selection and preparation: We selected 17 endometrial, 3 colorectal and 2 ovarian 453 
tumor-normal pairs for either whole-genome or whole-exome sequencing. Samples were all 454 
chemo-naïve. DNA was derived from fresh frozen, primary tumors. Matched normal DNA for 455 
these 22 samples was extracted from peripheral white blood cells.  456 
Whole-genome sequencing, analysis and annotation: 5 tumor-normal pairs were selected 457 
for whole-genome sequencing. Paired-end sequencing was performed using the Complete 458 
Genomics® service (CG, Mountain View, California, USA) as described in Drmanac et al 56 or 459 
by Illumina HiSeq2000. For CG sequencing, reads were initially mapped to the reference 460 
genome (hg18) using Complete Genomics’ CGAtools®. Between 207 and 338 Gb of 461 
sequencing data were obtained, resulting in a haploid coverage between 73x and 119x. 462 
Approximately 2.7x109 bases were called in each genome, representing ~95% of the total 463 
genome and ~97% of the exome. Substitutions and indels were called by the variant caller in 464 
the CGAtools®. On average, 3,132,715 substitions and 357,153 indels were detected in each 465 
genome. The CGAtool® (v1.0.3.9) calldiff method was used to detect somatic mutations in 466 
the tumor-normal pairs. For Illumina sequencing, 2x100bp paired-end sequencing was 467 
performed, yielding 25-30x coverage per sample. Burrows-Wheeler Alignment (BWA) was 468 
used to align the raw reads to the reference genome (hg19) 57. PCR duplicates were 469 
removed with Picard MarkDuplicates (v1.32). Base recalibration, local realignment around 470 
indels and single nucleotide variant calling were performed using the GenomeAnalysisToolKit 471 
(GATK v1.0.4487) 58. Small indels were detected using Dindel (v1.01) 59. Subsitutions and 472 
indels with quality score>Q30 were considered. On average, 3,977,086 substitutions and 473 
837,915 indels were detected in each genome. Somatic mutations were detected by means 474 
of intersectBed command of BEDTools (v2.12.0) 60. Raw data for all whole-genomes are 475 
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available under restricted access in the European Genome-Phenome Archive (EGA) with 476 
accession number EGAS00001000182.  477 
Sequence data were annotated using ANNOVAR (v2013Jun21) and the UCSC RefGene 478 
annotation track. Germ-line substitutions and indels were eliminated from the list of somatic 479 
mutations using the following publicly available datasets: (i) common SNPs in dbSNP (v132) 480 
with a minor allele frequency of >1%, (ii) substitutions identified in the November 2010 481 
release of the 1000 Genomes Project, (iii) the Axiom® Genotype Data Set containing 482 
common SNPs from 1261 HapMap3 individuals in 11 populations, and (iv) variant data 483 
identified in 46 HapMap individuals (CG diversity panel). Somatic mutations were validated 484 
using Sequenom MassARRAY genotyping, as previously described 15. Details of validation 485 
experiments are shown in Figure 1 – source data 3. A quality score method to enrich for true 486 
somatic mutations by defining a threshold that differentiates false-psotive and true-positive 487 
variants based on Sequenom validation data was applied to CG genomes and increased the 488 
validation rate for substitutions from 93.5%, 71.4% and 55.6% to 97.7%, 100% and 73.3% for 489 
MMR- 1, MMR+ 1 and MMR+ 2 respectively. Detailed data of all somatic mutations are in 490 
Figure 1 – source data 1 and Figure 1 – source data 2. Copy number status of the 491 
sequenced tumors were determined by Illumina CytoSNP-12 chips and analyzed using the 492 
ASCAT algorithm 61. Copy number status of the 5 whole-genomes was shown as Figure 1 – 493 
figure supplement 3. 494 
Genome annotation: The genome was annotated into the following functional genomic 495 
regions: (coding) exonic regions (1.12%), intronic regions (34.01%), 3’ untranslated regions 496 
(3’UTR, 0.78%), 5’ untranslated regions (5’UTR, 0.14%), noncoding RNA (ncRNA, 2.81%), 497 
upstream genic regions (defined as 1kb before the start of the gene, 0.58%), downstream 498 
genic regions (defined as 1kb after the end of the gene, 0.58%) and intergenic regions 499 
(59.98%). 500 
Data sets of germ-line and somatic variants: The following datasets were used: (i) the 501 
1000 Genomes Project containing common variants with a minor allellic frequency >10%, (ii) 502 
all germ-line variants identified in the 3 MMR-deficient tumors sequenced in this study, (iii) de 503 
novo mutations from 83 trios as published by Campell et al. and Kong et al 24,25 and (iv) a 504 
human-chimp divergence set of substitutions as previously described 62. Somatic mutations 505 
identified in other tumor whole-genomes were: (i) BRCA-deficient breast cancer tumors as 506 
published by Nik-Zainal et al 23, (ii) MMR-proficient endometrial tumors sequenced in this 507 
study, (iii) melanoma genomes as published by Pleasance et al 21 and (iv) small cell lung 508 
cancer (SCLC) as published by Pleasance et al  22. 509 
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Genomic features postulated to underlie the systematic variation of mutation rates: 510 
The distance to telomere was defined as the distance from the middle of the 1Mb window to 511 
the beginning or the end of the chromosome whichever was the shortest. Replication time 512 
was considered as published by Chen et al 63. Simple repeats represented the number of 513 
homopolymer and microsatellite bases. GC% was calculated as (G+C)/(A+T+G+C), CpG 514 
content as the number of CG dinucleotide bases, CpG islands as the number of bases 515 
belonging to CpG islands, gene content as the number of bases belonging to each genomic 516 
region. DNase hypersensitivity (DNAseI size) and nuclear lamina binding sites were 517 
downloaded from UCSC and the number of bases per site were counted for both. 518 
Exome-sequencing, analysis and annotation: We sequenced 11 tumor-normal pairs, 6 519 
primary cell cultures (PC) and their match normal DNA samples. Detailed clinical information 520 
is shown in Figure 4 – source data 1. Exomes were captured using Illumina's TruSeq Exome 521 
Enrichment Kit. The TruSeq capture regions encompass 62 Mb, consisting of 94.4%, 83.9% 522 
and 91.9% of the exonic, 5’UTR and 3’UTR regions respectively. 2x75bp paired-end 523 
sequencing reactions were used for all EM tumors, while 2x100bp paired-end sequencing 524 
was performed on CRC tumors and PC samples. Analysis, annotation and validation were 525 
performed similarly as for whole-genome sequencing. On average, the coverage was 44.5x 526 
and 95.1% of bases were called in the captured regions, yielding 51,782 substitutions and 527 
30,290 indels per sample. Raw data are available under restricted access in EGA under 528 
accession number EGAS00001000182. Details of validated somatic mutations are available 529 
in Figure 4 – source data 1 and Figure 4 – source data 2. 530 
Recurrent somatic mutations: The 13 MMR-deficient whole-exomes and whole-exome 531 
data extracted from 3 MMR-deficient whole-genomes were screened for recurrent mutations. 532 
Random selection and validation of 24 indels occurring in 6 or more samples revealed a 533 
validation rate of 100%. Given the high validation rate for somatic indels per se, and the even 534 
higher rate for recurrent indels, we considered all recurrent indels as true-positives. 535 
Subsequent analyses were limited to indels recurrently affecting homopolymer regions, i.e, 536 
29,663 Illumina TruSeq-captured exonic homopolymers. Details of recurrent mutations in 537 
these homopolymers are available in Figure 4 – source data 3. We also screened 5,430 and 538 
60,942 homopolymers located in the exome-captured 5’ and 3’ UTRs for recurrent indels. 539 
Details of these recurrent indels are in Figure 4 – source data 3. Recurrent indels meeting 540 
the following criteria were considered for a targeted Sequenom panel assessing MSI: (i) 541 
occurring in 6 or more samples, (ii) detected in both EM and CRC exomes, (iii) the maximal 542 
length of affected homopolymer<12bp. After extensive optimization experiments, 59 markers 543 
were chosen. Detailed information about each indel is given in Figure 5 – source data 1. 544 
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MSI panel: 236 EM tumors used to establish MSI thresholds were drawn from the Australian 545 
National Endometrial Cancer Study (ANECS). IHC analyses of these tumors were 546 
independently performed at the Molecular Cancer Epidemiology Laboratory in Brisbane, 547 
Australia as described 64. 11 out of 236 tumors were excluded for the 59-marker panel due to 548 
their low tumor percentage (≤10%). By varying the marker threshold, we calculated the 549 
number of true-positives and false-positives identified by our MSI panel relative to the IHC 550 
data. A ROC curve was constructed based on these values. The Matthew Correlation 551 
Coefficient of the ROC curve was calculated for each threshold. Tumors were considered 552 
MSI when they had 3 markers positive. We did not distinguish between MSI-low and 553 
microsatellite stable (MSS), as this is currently not clinically relevant. All tumors with less 554 
than 3 positive markers were thus considered MSS/MSI-L. For the Bethesda panel we 555 
defined three categories as follows: microsatellite stable (MSS, 0 out of 10 markers), low 556 
microsatellite instability (MSI-L, 1-2 out of 10 markers) and high microsatellite instability (MSI-557 
H, 3 or more out of 10 markers). Two sets of data (114 EM tumors and 97 CRC tumors) were 558 
used for the comparison. Details of these sample sets are given in Figure 5 – source data 1. 559 
Mutation signatures in other tumor types: The 59-marker panel was applied to ovarian 560 
tumors and leukemia. Four samples with proven MSI status were selected, including 1 561 
ovarian tumor (OV) and 3 leukemia cell lines (DND41, CCRF-CEM and SUPT1). The MSI-H 562 
OV tumor, 2 MSS OV tumors and their matched normal samples, as well as three MSI-H 563 
leukemia cell lines and a MSS leukemia cell line (RPMI-8402) were exome-sequenced. 564 
Detailed information for all samples can be found in Figure 5 – source data 2. Raw data are 565 
available in EGA under the accession number EGAS00001000182.  566 
Pathway analyses for recurrent mutations: Two pathway tools (IPA® and GenomeMuSiC) 567 
and three pathway databases (IPA®, BioCarta and Reactome 65) were used. We first selected 568 
all genes with somatic exonic indels, and then extended our mutation calling to indels 569 
occurring 25 bp up or down-stream of each exon. Mutation calling and filtering for the later 570 
set of mutations was done as described above. In total, 1,989 additional indels in exon/intron 571 
boundaries were detected. These were combined with the previously described indels in 572 
exonic regions, which - after removal of indels in MMR genes - yielded 7,546 indels in 4,116 573 
genes. As a validation, we selected 27 CRC and 65 EM tumors with MSI sequenced by The 574 
Cancer Genome Atlas 13,16. We selected genes recurrently affected not only by frameshift 575 
indels but also by non-synonymous substitutions. There were 2,183 and 3,138 genes from 576 
the CRC and EM tumor datasets, respectively. Detailed results of pathway analyses are 577 
given in Table 2 – source data 1. 578 
Establishment of primary tumor cell cultures: 11 primary endometrial and ovarian tumor 579 
cell cultures were established from tumors of patients undergoing surgery at the Division of 580 
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Gynecologic Oncology, UZ Leuven (Belgium). Tissue was washed with PBS supplemented 581 
with penicillin/streptomycin and fungizone, digested with collagenases type IV (1mg/ml; 582 
Roche) and DNAse I (0.1mg/ml; Roche) in RPMI+ medium. Single cell suspensions were 583 
prepared by filtration through a 70µm filter. Red blood cells were lysed using ammonium 584 
chloride (Stem Cell Technologies). Single cells were plated into a 25cm2 culture flask. After 585 
1-3 weeks, when cells reached 60-70% confluency, fibroblasts were removed using mouse 586 
anti-human CD90 (Clone AS02; Dianova) bound to Mouse Pan IgG Dynabeads (Life 587 
Technologies). Cell cultures were subsequently passaged at 70-90% confluency and banked 588 
at -80°C. Primary tumor cell cultures were grown in RPMI Medium 1640 supplemented with 589 
20% fetal bovine serum (FBS), 2mM L-Glutamine, 100U/ml penicillin, 100μg/ml streptomycin, 590 
1μg/ml fungizone and 10μg/ml gentamicin (Life Technologies) up to 25 passages.  591 
Immunofluorescent double staining for γH2AX and RAD51: Cells were seeded in 8-well 592 
Lab-tek Permanox Chamber slides (Nunc), treated for 24 hours, fixed in 4% 593 
paraformaldehyde for 15 minutes at room temperature, and ice-cold methanol for 5 minutes. 594 
Primary antibodies recognizing γH2AX (JBW301, Millipore) and RAD51 (PC130, Merck) 595 
followed by secondary antibodies conjugated to Alexa Fluor 647 and 488 (Life Technologies) 596 
were used. Images were acquired using an A1R Eclipse Ti inverted confocal microscope 597 
(Nikon) and processed using Fiji software, with compound or vehicle-treated cells being 598 
processed identically. Nuclei with >5 foci were scored as positive, and at least 200 nuclei 599 
were counted per condition by two independent individuals, blinded to the genotypes. 600 
Cell cycle analysis with BrdU and Propidium Iodide：Cells were treated for 24h with 601 
26µM olaparib, 0.3µM mitomycin C, 0.03µM camptothecin or carrier, and incubated for 90 602 
minutes with BrdU (10µM) before harvesting. Cells were resuspended in ice-cold PBS and 603 
ice-cold ethanol was slowly added to 70%. Cells were fixed for 5 minutes at room 604 
temperature, treated with 2M HCl for 30 minutes and stained with FITC-conjugated anti-BrdU 605 
antibody (BD). Cells were washed, resuspended in PI/RNase staining buffer (BD) and 606 
analyzed on a BD Biosciences FACSVerse flow cytometer. Cell cycle distributions were 607 
modeled using FlowJo software, and the fraction of cells in S-phase, G2/M and G1 608 
determined as described by Watson et al 66.  609 
Cytotoxicity screening: 5,000 cells/well were seeded in 96-well plates. After 24 hours, cells 610 
were treated in quadruplicate, incubated for 48 hours at 37°C and analyzed using the In Vitro 611 
Toxicology Assay Kit, Sulforhodamine B-based (Sigma) as per the manufacturers 612 
instructions. Growth inhibition was calculated as described 67.  613 
siRNA knockdown: siRNA ON-TARGETplus SMART pools (Thermo) were diluted in 614 
Optimem I reduced serum medium using Lipofectamine RNAiMAX (Life technologies) to 615 
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reverse transfect MCF7 cells For cytotoxicity screening, transfections were in 96-well format 616 
and medium was changed 14 hours after transfection. Cells were treated with olaparib 617 
(26μM) and after 48 hours processed for cytotoxicity screening. Simultaneously, siRNA 618 
transfections in 12-well plates were done to quantify knockdown.  619 
Gene expression: Total RNA was extracted using the RNeasy Mini kit (Qiagen) and reverse 620 
transcribed using the SuperScript III reverse transcription system (Life technologies). 621 
Quantitative RT-PCR (qRT-PCR) with ACTB an internal control was performed using 622 
TaqMan gene expression assay probes and 5μl TaqMan Fast Universal PCR master mix 623 
(Life technologies). Reactions were amplified in a Roche LightCycler 480 using the following 624 
cycles: 50°C (2min), 95°C (30sec), and 40 cycles of 95°C (3sec), 60°C (30 sec). 625 
 626 
A more detailed list of antibodies, compounds and other reagents used is described in Note 627 
S2.628 
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Figures 803 
Figure 1. Somatic mutations in MMR-deficient tumors. 804 
(a) The average frequency of mutations, indels and substitutions in MMR-deficient tumors 805 
versus MMR-proficient tumors, expressed as number of mutations per base (mpb). (b) The 806 
fraction of indels and substitutions observed in microsatellites, homopolymers (length over 5 807 
bp), short homopolymers (length of 3 to 5 bp) and ‘not in repeat regions’ compared to their 808 
expected fraction in these regions. (c-d) Frequencies of substitutions (c) and indels (d) in 809 
MMR-deficient tumors stratified into exonic, intergenic and intronic regions. (e) Indel 810 
frequencies corrected for homopolymer number, length and base composition. Indel 811 
frequencies in MMR-deficient tumors represent estimates only, as orthogonal technologies 812 
revealed false-positive rates of 12%, while false-negative rates in CG and Illumina whole-813 
genomes were estimated to be 27.7% and 0.5%, respectively, by Zook et al 68. In MMR-814 
proficient tumors all detected somatic indels were independently validated. 815 
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Figure 2. Somatic substitution patterns in MMR-deficient tumors. 817 
(a) Somatic substitution patterns in whole-genome sequences of MMR-deficient endometrial 818 
tumors (MMR-), matched germ-line (peripheral white blood cell) DNA from MMR-deficient 819 
tumors (MMR- germ-line), de novo mutations as identified in parent-offspring trios (de novo), 820 
1000 Genomes Project (1KG), the human-chimpanzee divergence panel (Divergence), 821 
melanoma and small-cell lung cancer (SCLC), BRCA-deficient breast tumors (BRCA-), MMR-822 
proficient endometrial tumors (MMR+). (b) Somatic substitution frequency per million 823 
dinucleotides and per million substitutions. The first row lists the base following the mutated 824 
base, the second row the base that was mutated and the third row the new base. Grey boxes 825 
indicate transitions. Frequencies are depicted color-coded following a logarithmic distribution 826 
as shown by the gradient on the left. (c-d) Squared coefficients of correlation (R2) between 827 
dinucleotide substitution patterns (c) and between the number of intergenic substitutions per 828 
1Mb window (d). Substitutions in MMR-proficient and de novo datasets were too sparse for 829 
correlations at a 1Mb scale. (e) Multivariate linear regression modeling of genomic features 830 
predicting substitutions frequencies per 1Mb window in MMR-deficient tumors, and the 831 
outcome of the same multivariate linear regression modeling in the germ-line genetic 832 
variability panels. T-values resulting from the linear model are displayed as bar plots and 833 
indicate direction and significance of correlation (shaded grey box equals P>0.05, Bonferroni-834 
corrected per model). The de novo substitution frequency was too low to be modeled at this 835 
resolution. (f) Frequency of transitions (excluding G:C>A:T in CG) and transversions per 1Mb 836 
window, binned per replication time. Frequencies are displayed relative to the earliest 837 
replicating bin. Linear regression analysis was performed to assess whether observed 838 
increases were significant and independent of other genomic features. All Bonferroni-839 
corrected P-values were significant (P<2.0E-5) except for transversions in MMR-deficient 840 
tumors, which were not significant (NS; P=0.23). (g) Effect of homopolymer nucleotide 841 
composition (An, Tn, Cn or Gn) on substitutions immediately flanking a homopolymer. For 842 
example, the nucleotide B next to the poly-A repeat “NNB(A)
n
BNN” is mostly converted to an 843 
A (NNB(A)
n
ANN) and not to a C, G or T. The modest increase in A substitutions next to Cn 844 
homopolymers and T substitutions near Gn homopolymers is caused by C:G>T:A transitions 845 
in a CpG context. (h) Substitution frequency in and outside CpG islands, relative to genome-846 
wide substitution frequencies. Data combined for all 3 MMR-deficient genomes are 847 
represented for (b,e-h), but individual MMR-deficient genomes display similar patterns 848 
(Figure 2 – figure supplement 1-5). 849 
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Figure 3. Somatic indel patterns in MMR-deficient tumors. 851 
(a) Impact of genomic features in MMR-deficient tumors on indel frequency as assessed by 852 
multivariate linear regression modeling. T-values resulting from the linear model are 853 
displayed for each genomic feature in the bar plots and indicate significance (shaded grey 854 
box equals P>0.05, Bonferroni-corrected per model) and direction of the correlation. (b) 855 
Fraction of all indels inserting or deleting the indicated number of bases. (c) Fraction of 856 
homopolymers affected by an indel stratified per nucleotide, compared to the genome-wide 857 
fraction of homopolymers with that nucleotide content.  858 
 859 
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Figure 4. Recurrent somatic indels. 861 
(a) The average mutation frequencies in the exons of 13 MMR-deficient tumors and 4 MMR-862 
proficient tumors. No obvious difference was observed between MLH1-, MSH2- and MSH6- 863 
deficiency in terms of the mutation frequencies, substitution patterns and indel compositions 864 
(Figure 4 – figure supplement 5). (b) Fraction of homopolymers affected by an indel in 865 
function of the homopolymer length stratified for exons, 5’ and 3’UTRs. (c) The fraction of 866 
homopolymers in exons, 5’ and 3’UTRs that are affected by an indel in function of the 867 
homopolymer length. (d) Average somatic indel frequencies in exons, 5’ and 3’UTRs of 16 868 
MMR-deficient tumors. (e) The enrichment of observed over expected frequencies of 869 
recurrent indels. Enrichments were stratified by length of the affected homopolymer and 870 
calculated for recurrent indels in 2, 3, 4 and 5 or more out of 16 MMR-deficient tumors. 871 
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Figure 5. The 56-marker panel for MSI testing. 873 
(a) Receiver-operator curve assessing the impact of the number of positive homopolymer 874 
markers (out of 59) on the sensitivity and specificity of MSI testing, based on a panel of 236 875 
EM tumors immunohistochemically characterized for their MMR status. (b) The Matthew 876 
Correlation Coefficient (MCC) of the ROC curve was calculated for each threshold, and a 877 
threshold of 3 resulted in the highest MCC-value (MCC=0.93). (c-d) The extended Bethesda 878 
panel and the 59-marker panel were compared in an independent series of 114 unselected 879 
primary endometrial tumors (c) and 126 stage II or III CRC tumors (d). Results were color-880 
coded according to high microsatellite instability (MSI-H; more than 1 markers positive), low 881 
microsatellite instability (MSI-L; 1 marker positive) or microsatellite stable status (MSS; 0 882 
markers positive) as determined with the extended Bethesda panel. For endometrial tumors, 883 
71 tumors (62%) were defined as MSS/MSI-L and 43 tumors (38%) as MSI-H by the 59-884 
marker panel. Out of these 43 MSI-H tumors, Bethesda identified 32 tumors as MSI-H (>2 885 
markers positive), 7 tumors as MSI-L and 5 tumors as MSS. Vice versa, Bethesda did not 886 
identify any MSI-H tumor that was not identified by our panel. For colorectal tumors, there 887 
were 97 MSS tumors in our 59-marker panel that were concordantly called MSS or MSI-L by 888 
the Bethesda panel. The remaining 29 samples were detected as MSI in the 59-marker 889 
panel. 28 of these were also called MSI-H by the Bethesda panel, whereas one was called 890 
MSS by the Bethesda panel. 891 
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Figure 6. Reduced DSBR by HR activity in MMR-deficient cells. 893 
(a) Representative confocal images of MMR-deficient and MMR-proficient primary tumor 894 
cells exposed for 24 hours to vehicle, 26 μM olaparib or 300nM mitomycin C stained for the 895 
homologous repair marker RAD51 (green), the DNA damage marker γH2AX (red) and 896 
counterstained with DAPI (blue). The bar is 10µm wide. (b) Quantification of cells containing 897 
>5 RAD51 or γH2AX foci. Averages are shown for MMR-deficient and MMR-proficient 898 
primary tumor cultures after 24 hours of treatment with vehicle, 26 μM olaparib or 300nM 899 
mitomycin C. 900 
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Figure 7. MMR-deficient cells are sensitive to PARP inhibition. 902 
(a) Dosimetry experiments assessing the effect of decreasing concentrations of olaparib on 903 
in vitro cell proliferation relative to the corresponding untreated cultures as measured by 904 
sulforhodamine B assays. (b) Cytotoxicity of olaparib, mitomycin C, ionizing radiation and 905 
paclitaxel as measured by sulforhodamine B assays. Displayed are the average 906 
concentrations (μM) or dose (Grey, Gy) that inhibit 50% of the normal growth. P-values are 907 
0.0077, 0.040 and 0.038 for olaparib, mitomycin C and ionizing radiation, while P-value is not 908 
significant (NS) for paclitaxel. (c) Effect of knock-down of BRCA1, BRCA2 and ATR mRNA 909 
on olaparib sensitivity of the MMR-proficient, HR-proficient MCF7 cell line. Cells were 910 
transfected with the indicated siRNA concentration (X axis), and after 24 hours incubated 911 
with 26µM olaparib or vehicle. Another 48 hours later, cell viability was assessed using the 912 
sulforhodamine B assay. The siRNA concentration corresponding to a growth inhibition of 913 
50% was subsequently assessed for the level of knock-down induced. The resulting values 914 
are indicated on the plots and are expressed as %. Values plotted were normalized to 915 
vehicle-treated cells transfected with a scrambled siRNA of matching concentration.  916 
 35 
Tables 917 
 918 
Table 1. Standard diagnostic tests to assess MMR-deficiency.  919 
Tumors and matched germ-line were whole-genome sequenced using either Complete 920 
Genomics or Illumina sequencing technology. For each tumor, microsatellite instability (MSI) 921 
using the extended Bethesda panel, standard immunohistochemistry of MMR proteins 922 
(MLH1, MSH2 and MSH6), and methylation status of the MLH1 promoter are shown. * a 923 
weak positive nuclear staining in the minority of the tumor cells. 924 
 925 
Tumor Histopathology Grade Stage 
Coverage  IHC 
MSI 
MLH1 hyper-
methylation 
Tumor 
Germ-
line 
 
MLH1 MSH2 MSH6 
MMR- 1 Endometrioid  3 IIIc 87.1 81.1  + + -(*) + - 
MMR- 2 Serous/clear cell 3 Ib 24.8 21.9  + - - - - 
MMR- 3 Endometrioid  2 Ib 28.5 30.0  - + + + + 
MMR+ 1 Endometrioid  3 I 119.4 73.1  + + + - + 
MMR+ 2 Serous  3 Ia 79.2 77.0  + + + - - 
926 
 36 
Table 2. Pathways most significantly affected by exonic indels. 927 
  928 
The 5 top ranking pathways are listed, as well as all annotated pathways relevant for DNA 929 
repair. The custom definition used throughout this manuscript was added for illustrative 930 
purposes. n.a. = not applicable. 931 
 932 
Database 
Pathway 
Rank FDR Affected 
samples 
(n=16) 
Mutations per 
sample 
**DSBR by HR (custom definition) n.a. n.a. 16 3.25 
BioCarta (ranking by GenomeMusic): 
**ATR/BRCA pathway 1 1.0E-16 15 3.50 
ATM pathway 2 5.9E-11 15 2.69 
G2 pathway 3 7.2E-08 15 2.81 
IL10 pathway 4 2.2E-05 12 1.75 
CARM1 and regulation of the Estrogen Receptor pathway 5 2.2E-05 14 3.19 
DNARepairDB (ranking by GenomeMusic): 
**Homologous recombination pathway 1 1.3E-04 13 1.56 
Base excision repair pathway 2 9.0E-02 10 0.75 
Non-homologous end joining pathway 3 1.7E-01 9 0.69 
Nucleotide excision repair pathway 4 8.3E-01 7 0.50 
Reactome (ranking by GenomeMusic): 
DNA repair 1 2.5E-11 15 6.69 
Double strand break repair 2 7.2E-08 15 2.94 
**Homologous recombination repair 3 1.9E-07 15 2.31 
G2/M checkpoints 4 2.3E-07 15 3.50 
Cell cycle checkpoints 5 4.5E-05 15 4.75 
Base excision repair 15 8.3E-03 10 0.94 
Non-homologous end joining 59 1.0E+00 8 0.63 
Nucleotide excision repair 61 5.9E-01 10 1.50 
IPA (ranking by IPA): 
**DNA double-strand break repair by homologous recombination 1 4.7E-03 15 1.56 
Ovarian cancer signaling  4.7E-03 16 5.75 
Role of NFAT in cardiac hypertrophy 3 6.8E-03 14 3.88 
Cell cycle: G2/M DNA damage checkpoint regulation 4 1.3E-02 15 2.88 
PPARα/RXRα activation 5 1.4E-02 15 4.63 
DNA double-strand break repair by non-homologous end joining 60 1.7E-01 14 1.50 
**The DSBR by HR pathway 933 
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